RhumbLine Advisers
DYN icon

RhumbLine Advisers’s Dyne Therapeutics DYN Stock Holding History

RhumbLine Advisers’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.26M Buy
202,535
+18,736
+10% +$430K ﹤0.01% 1647
2026
Q2 		$4.08M Sell
183,799
-3,424
-2% -$63.7K ﹤0.01% 1571
2026
Q1 		$3.39M Buy
187,223
+12,203
+7% +$210K ﹤0.01% 1598
2025
Q4 		$3.42M Buy
175,020
+7,200
+4% +$136K ﹤0.01% 1596
2025
Q3 		$2.12M Buy
167,820
+13,279
+9% +$151K ﹤0.01% 1877
2025
Q2 		$1.47M Buy
154,541
+20,914
+16% +$230K ﹤0.01% 2053
2025
Q1 		$1.4M Buy
133,627
+5,383
+4% +$77K ﹤0.01% 2007
2024
Q4 		$3.02M Buy
128,244
+3,734
+3% +$110K ﹤0.01% 1675
2024
Q3 		$4.47M Buy
124,510
+2,915
+2% +$116K ﹤0.01% 1485
2024
Q2 		$4.29M Buy
121,595
+23,266
+24% +$676K ﹤0.01% 1479
2024
Q1 		$2.79M Buy
98,329
+22,091
+29% +$500K ﹤0.01% 1735
2023
Q4 		$1.01M Buy
76,238
+5,667
+8% +$55.4K ﹤0.01% 2243
2023
Q3 		$632K Buy
70,571
+6,659
+10% +$71.7K ﹤0.01% 2471
2023
Q2 		$719K Buy
63,912
+12,732
+25% +$150K ﹤0.01% 2469
2023
Q1 		$590K Buy
51,180
+1,966
+4% +$25.5K ﹤0.01% 2372
2022
Q4 		$570K Buy
49,214
+396
+0.8% +$4.58K ﹤0.01% 2402
2022
Q3 		$620K Buy
48,818
+4,436
+10% +$50.9K ﹤0.01% 2401
2022
Q2 		$305K Buy
44,382
+6,938
+19% +$47.8K ﹤0.01% 2744
2022
Q1 		$361K Sell
37,444
-661
-2% -$5.63K ﹤0.01% 2572
2021
Q4 		$453K Sell
38,105
-285
-0.7% -$4K ﹤0.01% 2547
2021
Q3 		$623K Buy
38,390
+1,400
+4% +$24.8K ﹤0.01% 2439
2021
Q2 		$778K Buy
36,990
+25,442
+220% +$478K ﹤0.01% 2353
2021
Q1 		$179K Buy
+11,548
New +$223K ﹤0.01% 2858

Other funds holding DYN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Atlas Venture Life Science Advisors
Atlas Venture Life Science Advisors Cambridge, Massachusetts $631M AUM 38.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

RhumbLine Advisers's DYN Position: Q3 2026 in Review

RhumbLine Advisers increased its Dyne Therapeutics (DYN) stake by 10% in Q3 2026, buying an estimated $430K and bringing the position to 202,535 shares worth $3.26M. The position accounts for ﹤0.01% of the portfolio, ranked #1647.

RhumbLine Advisers first reported a position in DYN in Q1 2021 and has held it in 23 quarters since. The position peaked at $4.47M in Q3 2024. 133 funds tracked by Wall St. Rank hold DYN as of Q3 2026.

  • RhumbLine Advisers held 202,535 shares of Dyne Therapeutics worth $3.26M as of Q3 2026.
  • RhumbLine Advisers bought 18,736 Dyne Therapeutics shares in Q3 2026, an estimated $430K.
  • Dyne Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #1647 holding.
  • RhumbLine Advisers first reported a position in Dyne Therapeutics in Q1 2021 and has held it in 23 quarters since.
  • RhumbLine Advisers's Dyne Therapeutics position peaked at $4.47M in Q3 2024.
  • 133 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.